Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00661635 · ClinicalTrials.gov registry record · Phase 3
A Randomized, Double-Blind Study of the Efficacy and Safety of Valdecoxib Compared to Placebo for Treatment of Post- Cholecystectomy Surgery Pain
A Phase 3 study of Pain and Laparoscopic Cholecystectomy, sponsored by Pfizer.
- Completed
- Registry status
- Phase 3
- Development phase
- 490
- Enrollment target
- 20
- Study locations
NCT00661635: Completed Phase 3 study of Pain and Laparoscopic Cholecystectomy, sponsored by Pfizer.
NCT00661635 is a Phase 3 study of Pain and Laparoscopic Cholecystectomy that has completed, run by Pfizer. The registered enrollment target is 490 participants, above the 303-participant average among 374 other Pain trials with a reported enrollment target (62% higher). The trial reports 20 study locations across 3 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00661635, a Phase 3 study of Pain and Laparoscopic Cholecystectomy, has completed, sponsored by Pfizer.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 490 participants
- Enrollment target
- 20
- Study locations
Study Summary
To evaluate the analgesic efficacy, general safety, and effects on health outcome measures and opioid-related symptoms of 2 valdecoxib dosing regimens compared with placebo in patients with moderate or severe pain following laparoscopic cholecystectomy surgery.
Conditions Studied
Interventions
- DRUG placebo
- DRUG valdecoxib
Study Locations (20)
Arizona
- Pfizer Investigational Site - Glendale
- Pfizer Investigational Site - Glendale
- Pfizer Investigational Site - Phoenix
- Pfizer Investigational Site - Phoenix
- Pfizer Investigational Site - Phoenix
- Pfizer Investigational Site - Phoenix
- Pfizer Investigational Site - Tucson
- Pfizer Investigational Site - Tucson
- Pfizer Investigational Site - Tucson
Alabama
- Pfizer Investigational Site - Birmingham
- Pfizer Investigational Site - Daphne
- Pfizer Investigational Site - Fairhope
- Pfizer Investigational Site - Mobile
- Pfizer Investigational Site - Mobile
- Pfizer Investigational Site - Sheffield
California
- Pfizer Investigational Site - Anaheim
- Pfizer Investigational Site - Bakersfield
- Pfizer Investigational Site - Bakersfield
- Pfizer Investigational Site - Los Angeles
- Pfizer Investigational Site - Los Angeles
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 490 participants |
| Start Date | 2002-11 |
| Est. Completion | 2003-07 |
| Phase | Phase 3 |
What the finished NCT00661635 record still lists
NCT00661635 is an interventional study that assigns participants to a tested intervention. The registered 490 participants enrollment target is mid-sized for trials with a published cap, above the 303-participant average among 374 other Pain trials with a reported enrollment target (62% higher).
The record links to 2 conditions, with Pain appearing as the primary indexed condition, and to 2 interventions - of which placebo is the first listed.
NCT00661635 names 20 study sites across 3 states, led by Arizona, Alabama, California.
Frequently Asked Questions
What is clinical trial NCT00661635 about?
NCT00661635 is a clinical study titled "A Randomized, Double-Blind Study of the Efficacy and Safety of Valdecoxib Compared to Placebo for Treatment of Post- Cholecystectomy Surgery Pain". To evaluate the analgesic efficacy, general safety, and effects on health outcome measures and opioid-related symptoms of 2 valdecoxib dosing regimens compared with placebo in patients with moderate or severe pain following laparoscopic cholecystectomy surgery.
What is the current status of trial NCT00661635?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 490 participants. The study started on 2002-11. Estimated completion is 2003-07.
What conditions does trial NCT00661635 study?
This clinical trial studies the following conditions: Pain, Laparoscopic Cholecystectomy.
What interventions are being tested in trial NCT00661635?
The interventions under investigation include: placebo (DRUG), valdecoxib (DRUG).
Who is sponsoring clinical trial NCT00661635?
This trial is sponsored by Pfizer, which has 1,845 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00661635 being conducted?
This trial has 20 study locations across Alabama, Arizona, California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Pain
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT00661635's enrollment target sits among peer trials
490 34th of 374 higher than 341 of 374 other Pain trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Pain trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Effect of NSAIDs on Union, Opioid Utilization and Pain Management for Tibia Fractures: A Pragmatic, Randomized Controlled Trial
RECRUITING · Phase 3
-
Opioid-Free Orthopaedics
RECRUITING · Phase 3
-
Suzetrigine in Total Hip Arthroplasty
RECRUITING · Phase 3
-
Optimizing Chronic Pain Care With Mindfulness and Chronic Pain Management Visits
RECRUITING · Phase 3
-
Implementation and Effectiveness of Mindfulness Oriented Recovery Enhancement as an Adjunct to Methadone Treatment
RECRUITING · Phase 3
-
Post-Op Pain Control for Prophylactic Intramedullary Nailing.
RECRUITING · Phase 3
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04728893 · 490 participants · Phase 2
Efficacy and Safety of Nemtabrutinib (MK-1026) in Participants With Hematologic Malignancies (MK-1026-003)
- NCT06238479 · 490 participants · Phase 1
A Study of LY4101174 in Participants With Recurrent, Advanced or Metastatic Solid Tumors
- NCT06336928 · 490 participants
A Validation Study to Determine Concordance of Liquid Biopsy and Breast Cancer Diagnosis
- NCT06641414 · 490 participants · Phase 3
Lisaftoclax (APG-2575) Combined With Azacytidine (AZA) in the Treatment of Patients With Higher-risk Myelodysplastic Syndrome (GLORA-4).
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia